Brief: AB Science Gets FDA Authorization To Start Clinical Development Program Of Masitinib

AB Science SA

04/10/2021 17:16

Oct 4 (Reuters) - AB Science SA  ABS.PA :
    * RECEIVES FDA AUTHORIZATION TO START CLINICAL DEVELOPMENT
PROGRAM
OF MASITINIB IN MAST CELL ACTIVATION SYNDROME (MCAS)
    * INVESTIGATIONAL NEW DRUG (IND) APPROVAL LETTER RECEIVED
FROM FDA
PROVIDES AUTHORITY TO PROCEED WITH A PHASE II STUDY (AB20006) IN
PATIENTS WITH SEVERE MAST CELL ACTIVATION SYNDROME
    * STUDY WILL ENROLL 60 PATIENTS FROM NUMEROUS STUDY CENTERS
    * TREATMENT OBJECTIVE IN SEVERE MCAS IS TO REDUCE SYMPTOMS
(PRURITUS, FLUSH, DEPRESSION) AND IMPROVE IMPAIRED
QUALITY-OF-LIFE

Source text for Eikon:  ID:nGNE82lShx 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))